Structure-guided design of multi-epitopes vaccine against variants of concern (VOCs) of SARS-CoV-2 and validation through In silico cloning and immune simulations
Copyright © 2021 Elsevier Ltd. All rights reserved..
Severe Acute Respiratory Syndrome Corovirus2 (SARS-CoV-2) has been determined to be the cause of the current pandemic. Typical symptoms of patient having COVID-19 are fever, runny nose, cough (dry or not) and dyspnea. Several vaccines are available in markets that are tackling current pandemic. Many different strains of SAR-CoV-2 have been evolved with the passage of time. The emergence of VOCs particularly the B.1.351 ("South African") variant of SARS-CoV-2 has been reported to be more resistant than other SARS-CoV-2 strains to the current vaccines. Thus, the current research is focused to design multi-epitope subunit Vaccine (MEV) using structural vaccinology techniques. As a result, the designed MEV exhibit antigenic properties and possess therapeutic features that can trigger an immunological response against COVID-19. Furthermore, validation of the MEV using immune simulation and in silico cloning revealed that the proposed vaccine candidate effectively triggered the immune response. Conclusively, the developed MEV needs further wet lab exploration and could be a viable vaccine to manage and prevent COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:140 |
|---|---|
| Enthalten in: |
Computers in biology and medicine - 140(2022) vom: 01. Jan., Seite 105122 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Humayun, Fahad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immune simulation |
|---|
| Anmerkungen: |
Date Revised 21.12.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.compbiomed.2021.105122 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33433375X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33433375X | ||
| 003 | DE-627 | ||
| 005 | 20231227135119.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.compbiomed.2021.105122 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1234.xml |
| 035 | |a (DE-627)NLM33433375X | ||
| 035 | |a (NLM)34896886 | ||
| 035 | |a (PII)S0010-4825(21)00916-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Humayun, Fahad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structure-guided design of multi-epitopes vaccine against variants of concern (VOCs) of SARS-CoV-2 and validation through In silico cloning and immune simulations |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Severe Acute Respiratory Syndrome Corovirus2 (SARS-CoV-2) has been determined to be the cause of the current pandemic. Typical symptoms of patient having COVID-19 are fever, runny nose, cough (dry or not) and dyspnea. Several vaccines are available in markets that are tackling current pandemic. Many different strains of SAR-CoV-2 have been evolved with the passage of time. The emergence of VOCs particularly the B.1.351 ("South African") variant of SARS-CoV-2 has been reported to be more resistant than other SARS-CoV-2 strains to the current vaccines. Thus, the current research is focused to design multi-epitope subunit Vaccine (MEV) using structural vaccinology techniques. As a result, the designed MEV exhibit antigenic properties and possess therapeutic features that can trigger an immunological response against COVID-19. Furthermore, validation of the MEV using immune simulation and in silico cloning revealed that the proposed vaccine candidate effectively triggered the immune response. Conclusively, the developed MEV needs further wet lab exploration and could be a viable vaccine to manage and prevent COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immune simulation | |
| 650 | 4 | |a In silico cloning | |
| 650 | 4 | |a Multi-epitope subunit vaccine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Structural vaccinology | |
| 700 | 1 | |a Cai, Yutong |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Farhan, Syed Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Rana, Usman Ishrat |e verfasserin |4 aut | |
| 700 | 1 | |a Qamar, Anum Binte |e verfasserin |4 aut | |
| 700 | 1 | |a Fawad, Nasim |e verfasserin |4 aut | |
| 700 | 1 | |a Shamas, Shazia |e verfasserin |4 aut | |
| 700 | 1 | |a Dongqing-Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Computers in biology and medicine |d 1970 |g 140(2022) vom: 01. Jan., Seite 105122 |w (DE-627)NLM000382272 |x 1879-0534 |7 nnns |
| 773 | 1 | 8 | |g volume:140 |g year:2022 |g day:01 |g month:01 |g pages:105122 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.compbiomed.2021.105122 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 140 |j 2022 |b 01 |c 01 |h 105122 | ||